[{"orgOrder":0,"company":"Valbiotis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VALBIOTIS Accelerates Its Pipeline Clinical Development in New Indications: Cardiovascular and Hepatic Steatosis Risk Reduction","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"FRANCE","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Valbiotis"},{"orgOrder":0,"company":"Valbiotis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VALBIOTIS Receives US and European TOTUM-070 Patent for Reducing Hypercholesterolemia","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"FRANCE","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Valbiotis"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
TOTUM-070 is a combination of plant extracts that contains neither phytosterols nor red yeast rice, designed by VALBIOTIS’ proprietary R&D platform based in Riom (63).
VALBIOTIS expects to start a Phase II clinical trial evaluating the effect of TOTUM-070 in reducing LDL-cholesterol, in mild to moderate hypercholesterolemic patients.